# Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)

> **NCT01352338** · PHASE1,PHASE2 · COMPLETED · sponsor: **UMC Utrecht** · enrollment: 82 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide, endoxan, prednisone
- **DRUG:** lenalidomide, endoxan, prednisone

## Key facts

- **NCT ID:** NCT01352338
- **Lead sponsor:** UMC Utrecht
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2014-11
- **Final completion:** 2016-02
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2016-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01352338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01352338, "Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT01352338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*